{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:39:37Z","timestamp":1790005177240,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40262-015-0314-y","type":"journal-article","created":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T15:08:21Z","timestamp":1441811301000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Drug\u2013Drug Interactions with the NS3\/4A Protease Inhibitor Simeprevir"],"prefix":"10.1007","volume":"55","author":[{"given":"Sivi","family":"Ouwerkerk-Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Snoeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beumont-Mauviel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Simion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,9]]},"reference":[{"issue":"1","key":"314_CR1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41\u201352.","journal-title":"N Engl J Med."},{"issue":"4","key":"314_CR2","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433\u201344.","journal-title":"Hepatology."},{"key":"314_CR3","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society\u2014USA. Recommendations for testing, managing, and treating hepatitis C [online]. http:\/\/www.hcvguidelines.org . Published 21 March 2014. Accessed 20 Aug 2014."},{"issue":"9941","key":"314_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403\u201313.","journal-title":"Lancet."},{"key":"314_CR5","unstructured":"European Medicines Agency. OLYSIO 150 mg hard capsules: summary of product characteristics [online]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002777\/WC500167869.pdf . Published 06 Apr 2014. Accessed 30 Jun 2014."},{"issue":"6","key":"314_CR6","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","volume":"58","author":"MW Fried","year":"2013","unstructured":"Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918\u201329.","journal-title":"Hepatology."},{"issue":"7","key":"314_CR7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669\u201379.","journal-title":"Gastroenterology."},{"issue":"2","key":"314_CR8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","volume":"146","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146(2):430\u201341.","journal-title":"Gastroenterology."},{"issue":"9941","key":"314_CR9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414\u201326.","journal-title":"Lancet."},{"issue":"9956","key":"314_CR10","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756\u201365.","journal-title":"Lancet."},{"key":"314_CR11","unstructured":"OLYSIO (simeprevir) capsules: package insert. Titusville: Janssen Pharmaceuticals, Inc; 2013. https:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf . Published Nov 2013. Accessed 30 Jun 2014."},{"key":"314_CR12","unstructured":"Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus pegIFN\/ribavirin in HCV genotype-1\/HIV coinfection (study no.\u00a0C212) [oral presentation]. Presented at: 21st conference on retroviruses and opportunistic infections (CROI); March 3\u20136, 2014; Boston, MA, USA."},{"key":"314_CR13","doi-asserted-by":"crossref","unstructured":"Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin in treatment-na\u00efve or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial [poster]. Presented at: 49th annual meeting of the European Association for the Study of the Liver (EASL); April 9\u201313, 2014; London.","DOI":"10.1016\/S0168-8278(14)61486-0"},{"key":"314_CR14","unstructured":"Fried MW, Buti M, Dore GJ. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIB study [oral presentation]. Presented at: 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD); November 4\u20138, 2011; San Francisco, CA, USA."},{"issue":"6","key":"314_CR15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/1060028015576180","volume":"49","author":"S Burgess","year":"2015","unstructured":"Burgess S, Partovi N, Yoshida EM, et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015;49(6):674\u201387.","journal-title":"Ann Pharmacother."},{"issue":"3","key":"314_CR16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138(3):913\u201321.","journal-title":"Gastroenterology."},{"key":"314_CR17","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. The effect of food and different meal types on the bioavailability of simeprevir (TMC435), an HCV protease inhibitor in clinical development [poster no. 0_20]. Presented at: 8th international workshop on clinical pharmacology of hepatitis therapy; June 26\u201327, 2013; Cambridge, MA, USA."},{"key":"314_CR18","first-page":"5","volume":"6","author":"A Simion","year":"2013","unstructured":"Simion A, Mortier S, Peeters M, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with severe renal impairment [abstract no. O_03_PK]. Rev Antiviral Ther Infec Dis. 2013;6:5.","journal-title":"Rev Antiviral Ther Infec Dis"},{"key":"314_CR19","first-page":"6","volume":"6","author":"S Ouwerkerk-Mahadevan","year":"2013","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment [abstract no.\u00a0O_04_PK]. Rev Antiviral Ther Infec Dis. 2013;6:6.","journal-title":"Rev Antiviral Ther Infec Dis"},{"key":"314_CR20","unstructured":"Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters [poster]. Presented at: 61st annual meeting of the American Association for the Study of Liver Disease (AASLD); October 29 to November 2, 2010; San Francisco, CA, USA."},{"key":"314_CR21","doi-asserted-by":"crossref","unstructured":"Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers [poster]. Presented at: 45th annual meeting of the European Association for the Study of the Liver (EASL); April 14\u201318, 2010; Vienna.","DOI":"10.1016\/S0168-8278(10)61077-X"},{"issue":"5","key":"314_CR22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-014-0142-5","volume":"53","author":"CT Kanter de","year":"2014","unstructured":"de Kanter CT, Drenth JP, Arends JE, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014;53(5):409\u201327.","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"314_CR23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/COH.0b013e3282f82bf1","volume":"3","author":"L Dickinson","year":"2008","unstructured":"Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS. 2008;3(3):296\u2013305.","journal-title":"Curr Opin HIV AIDS."},{"issue":"10","key":"314_CR24","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00228-013-1525-5","volume":"69","author":"PN Morcos","year":"2013","unstructured":"Morcos PN, Moreira SA, Brennan BJ, et al. Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol. 2013;69(10):1777\u201384.","journal-title":"Eur J Clin Pharmacol."},{"issue":"7","key":"314_CR25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3851\/IMP1648","volume":"15","author":"A Jetter","year":"2010","unstructured":"Jetter A, Fatkenheuer G, Frank D, et al. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther. 2010;15(7):975\u201383.","journal-title":"Antivir Ther."},{"key":"314_CR26","unstructured":"Ouwerkerk-Mahadevan S, Sekar V, Peeters M, et al. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers [presentation]. Presented at: 19th conference on retroviruses and opportunistic infections (CROI); March 5\u20138, 2012; Seattle, WA, USA."},{"key":"314_CR27","unstructured":"Ribasphere\u00ae (ribavirin USP) tablets: package insert. Warrendale: Kadmon Pharmaceuticals, LLC; 2012. https:\/\/kadmon.com\/files\/ribasphere-tablets-pi.pdf . Published Feb 2012. Accessed 10 Aug 2014."},{"issue":"2","key":"314_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","volume":"46","author":"H Zhang","year":"2007","unstructured":"Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133\u201357.","journal-title":"Clin Pharmacokinet."},{"issue":"1\u20132","key":"314_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsbmb.2007.09.025","volume":"110","author":"T Korhonen","year":"2008","unstructured":"Korhonen T, Turpeinen M, Tolonen A, et al. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008;110(1\u20132):56\u201366.","journal-title":"J Steroid Biochem Mol Biol."},{"key":"314_CR30","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone [poster]. Presented at: 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD); November 9\u201313, 2012; Boston, MA, USA."},{"issue":"4","key":"314_CR31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.11.013","volume":"60","author":"S Tischer","year":"2014","unstructured":"Tischer S, Fontana RJ. Drug\u2013drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60(4):872\u201384.","journal-title":"J Hepatol."},{"key":"314_CR32","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus [oral presentation]. Presented at: 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD); November 9\u201313, 2012; Boston, MA, USA."},{"issue":"4","key":"314_CR33","first-page":"370","volume":"23","author":"Z Pavlovic","year":"2011","unstructured":"Pavlovic Z, Delic D, Maric NP, et al. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. Psychiatr Danub. 2011;23(4):370\u20137.","journal-title":"Psychiatr Danub."},{"issue":"1","key":"314_CR34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","volume":"26","author":"E Spina","year":"2012","unstructured":"Spina E, Trifiro G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39\u201367.","journal-title":"CNS Drugs."},{"key":"314_CR35","unstructured":"Ouwerkerk-Mahadevan S, Beumont-Mauviel M, Simion A, et al. The pharmacokinetic interaction between the investigational HCV NS3\/4A protease inhibitor TMC435 and escitalopram [poster]. Presented at: 62nd annual meeting of the American Association for the Study of Liver Disease (AASLD); November 4\u20138, 2011; San Francisco, CA, USA."},{"issue":"Suppl 1","key":"314_CR36","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/cis392","volume":"55","author":"JW Ward","year":"2012","unstructured":"Ward JW, Valdiserri RO, Koh HK. Hepatitis C virus prevention, care, and treatment: from policy to practice. Clin Infect Dis. 2012;55(Suppl 1):S58\u201363.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"314_CR37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","volume":"321","author":"RA Totah","year":"2007","unstructured":"Totah RA, Allen KE, Sheffels P, et al. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321(1):389\u201399.","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"314_CR38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","volume":"84","author":"ED Kharasch","year":"2008","unstructured":"Kharasch ED, Bedynek PS, Park S, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008;84(4):497\u2013505.","journal-title":"Clin Pharmacol Ther."},{"key":"314_CR39","unstructured":"Ouwerkerk-Mahadevan S, Beumont-Mauviel M, De Smedt G, et al. The pharmacokinetic interaction between the investigational NS3\/4A HCV protease inhibitor TMC435 and methadone [poster]. Presented at: 62nd annual meeting of the American Association for the Study of Liver Disease (AASLD); November 4\u20138, 2011; San Francisco, CA, USA."},{"key":"314_CR40","unstructured":"European Medicines Agency. Daklinza 30\u00a0mg film-coated tablets: summary of product characteristics [online]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf . Published 15 Sept 2014. Accessed 18 Sept 2014."},{"key":"314_CR41","unstructured":"Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [poster]. Presented at: IDWeek; October 17\u201321, 2012; San Diego, CA, USA."},{"key":"314_CR42","unstructured":"Sovaldi\u2122 (sofosbuvir) tablets: package insert. Foster City: Gilead Sciences, Inc; 2013. https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/sovaldi\/sovaldi_pi.pdf . Published Dec 2013. Accessed 10 Aug 2014."},{"issue":"6","key":"314_CR43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","volume":"29","author":"SF Zhou","year":"2007","unstructured":"Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687\u2013710.","journal-title":"Ther Drug Monit."},{"issue":"9","key":"314_CR44","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003088-200746090-00002","volume":"46","author":"M Rittweger","year":"2007","unstructured":"Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007;46(9):739\u201356.","journal-title":"Clin Pharmacokinet."},{"key":"314_CR45","unstructured":"Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [poster]. Presented at: IDWeek; October 17\u201321, 2012; San Diego, CA, USA."},{"issue":"3","key":"314_CR46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdd.749","volume":"32","author":"MK Choi","year":"2011","unstructured":"Choi MK, Jin QR, Choi YL, et al. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug\u2013drug interactions. Biopharm Drug Dispos. 2011;32(3):175\u201384.","journal-title":"Biopharm Drug Dispos."},{"issue":"1","key":"314_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","volume":"29","author":"AM Baciewicz","year":"2013","unstructured":"Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1\u201312.","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"314_CR48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00228-013-1634-1","volume":"70","author":"P Naidoo","year":"2014","unstructured":"Naidoo P, Chetty VV, Chetty M. Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol. 2014;70(4):379\u201389.","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"314_CR49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.106.012765","volume":"35","author":"J Weiss","year":"2007","unstructured":"Weiss J, Theile D, Ketabi-Kiyanvash N, et al. Inhibition of MRP1\/ABCC1, MRP2\/ABCC2, and MRP3\/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2007;35(3):340\u20134.","journal-title":"Drug Metab Dispos."},{"key":"314_CR50","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Peeters M, et al. Summary of pharmacokinetic drug\u2013drug interactions for simeprevir (TMC435), a hepatitis C virus NS3\/4A protease inhibitor [poster]. Presented at: 14th European AIDS Conference (EACS); October 16\u201319, 2013; Brussels."},{"issue":"10","key":"314_CR51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin B, Drouot S, Barrail-Tran A, et al. Drug\u2013drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815\u201331.","journal-title":"Clin Pharmacokinet."},{"key":"314_CR52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/2193-1801-3-168","volume":"3","author":"M Zhelyazkova-Savova","year":"2014","unstructured":"Zhelyazkova-Savova M, Gancheva S, Sirakova V. Potential statin\u2013drug interactions: prevalence and clinical significance. Springerplus. 2014;3:168.","journal-title":"Springerplus."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0314-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0314-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0314-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T05:14:20Z","timestamp":1567142060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0314-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,9]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0314-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,9]]}}}